资讯

MPR3 天
JAK1 Inhibitor Designated Orphan Drug for Eosinophilic Granulomatosis With Polyangiitis
NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.
European Medical Journal6 天
Reduced Mepolizumab Dose Effective for Long-Term EGPA Control
A real-life study suggests that stepping down mepolizumab dosage in EGPA patients in remission is effective, with no asthma ...
MedCity News25 天
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...
NS Pharma gets FDA orphan drug status for autoimmune disease
NS Pharma, a unit of Nippon Shinyaku (OTCPK:NPNKF), said on Monday that the U.S. FDA has granted orphan drug designation to ...
Morningstar6 天
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic ...
1) Bell, CF., Lau, M., Shen, Q. Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United ...
Rheumatology Advisor12 天
Long-Term Mepolizumab Use in EGPA Is Safe, Reduces Corticosteroid Dependence
Long-term treatment with mepolizumab, an interleukin-5 inhibitor, demonstrates a favorable safety profile and sustained corticosteroid-sparing benefits among patients with eosinophilic granulomatosis ...